CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial

CPX-351 Pharmacokinetics and Safety in Adults with Hematologic Malignancies and Renal Function Impairment: Phase 1 Trial

This open-label phase 1 study (clinicaltrials.gov, NCT03555955) assessed CPX-351 pharmacokinetics (PK) and safety in patients with hematologic malignancies with normal or impaired renal function. Patients were enrolled into three cohorts based on their creatinine clearance (CrCl): ≥90 mL/min (Cohort...

Full description

Bibliographic Details
Main Authors: Scott R. Solomon, Bayard L. Powell, Jamie Koprivnikar, Catherine Lai, Heather Male, Laura C. Michaelis, Laura F. Newell, David Sanford, Jack Jenkins, Amy Zelaya, Sheryl Coppola, Stefan Faderl, Roland B. Walter
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Cancers
Subjects:
CPX-351
hematologic cancer
pharmacokinetics
renal impairment
Online Access:https://www.mdpi.com/2072-6694/16/5/915

Internet

https://www.mdpi.com/2072-6694/16/5/915

Similar Items